TNFRSF9 and neoplasm: Compared to the huIgG4-MSNs and PBS treatment which served as negative controls, treatment with rhCD137L-MSNs and ure-MSNs profoundly and significantly reduced the growth of both C666 and C666-CD137 tumors, with rhCD137L-MSNs inducing a further tumor reduction than ure-MSNs (Figure 5B-D).